No Detail Found!

Comparative efficacy and safety of mitomycin-C vs. BCG in non-muscle invasive bladder cancer

Author(s)
Muhammad Yahya Illahi Departments of Urology, Benazir Institute of Urology and Transplantation (BIUT), Rawalpindi, Pakistan
Asadullah Departments of Urology, Benazir Institute of Urology and Transplantation (BIUT), Rawalpindi, Pakistan
Jamal Mustafa Khan Departments of Urology, Benazir Institute of Urology and Transplantation (BIUT), Rawalpindi, Pakistan
Jaikumar Departments of Urology, Benazir Institute of Urology and Transplantation (BIUT), Rawalpindi, Pakistan
Izhar-ul-Haq Peoples University of Medical and Health Sciences (PUMHS), Nawab Shah, Pakistan
Rashid Ali Siyal Departments of Urology, Benazir Institute of Urology and Transplantation (BIUT), Rawalpindi, Pakistan
Abstract
Objective: This study compares the efficacy and side effect profiles of Bacillus Calmette-Guerin (BCG) and Mitomycin-C (MMC) in managing Non-Muscle Invasive Bladder Cancer (NMIBC), focusing on recurrence-free survival (RFS), progression-free survival (PFS) and adverse events. Methods: This retrospective sectional study was conducted at Department of Urology, Peoples University of Medical and Health Sciences, Nawab Shah from September 2021 to April 2022. It included 200 histologically confirmed NMIBC patients, treated with BCG (n=100) or MMC (n=100) after transurethral resection of bladder tumor (TURBT). RFS, PFS, and adverse events were analyzed over a 12-month followup. Results: BCG demonstrated significantly higher RFS (85% vs. 78%, p=0.041) and PFS (92% vs. 88%, p=0.032) compared to MMC. Adverse events were more frequent in the BCG group, including cystitis (30% vs. 18%, p=0.032) and fever (15% vs. 5%, p=0.002). Logistic regression identified high-grade tumors (OR: 2.34, p=0.001) and tumor size >3 cm (OR: 1.78, p=0.021) as predictors of recurrence. Conclusion: BCG was more effective in preventing recurrence and progression in NMIBC but was associated with higher toxicity. MMC remains a viable alternative for intermediate-risk patients and those intolerant to BCG.
Publication Details
Page(s) 54-57
DOI DOI not available
Published Journal: Rawal Medical Journal, Volume: 50, Issue: 1, Year: 2025

Request the full text from PASTIC

Keywords
Mitomycin-C, Bacillus Calmette-Guérin, Recurrencefree Recurrencefree therapy., Non-muscle invasive bladder cancer
References
Sung H,Ferlay J,Siegel RL,Laversanne M,Soerjomataram I,Jemal A .2021 .a cancer journal for clinicians. Global cancer statistics, 71 : 209-49.
Cathomas R,Lorch A,Bruins HM,Compérat EM,Cowan NC,Efstathiou JA .2022 .The 2021 updated European Association of Urology guidelines on metastatic urothelial carcinoma. Eur Urol, 81 : 95-103.
Ślusarczyk A,Garbas K,Pustuła P,Zapała Ł,Radziszewski P .2024 .Assessing the Predictive Accuracy of EORTC, CUETO and EAU Risk Stratification Models for High-Grade Recurrence and Progression after Bacillus Calmette-Guérin Therapy in Non-Muscle-Invasive Bladder Cancer. Cancers, 16 : 1684-8.
Saginala K,Barsouk A,Aluru JS,Rawla P,Padala SA,Barsouk A .2020 .Epidemiology of bladder cancer. Med Sci, 8 : 15-9.
Holzbeierlein JM,Bixler BR,Buckley DI,Chang SS,Holmes R,James AC .2024 .Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment. J Urol, 211 : 10-97.
Lazebnik T. .2022 .Cell-level spatio-temporal model for a Bacillus Calmette-Guérin-based immunotherapy treatment protocol of superficial bladder cancer. Cells, 11 : 2372-6.
Wang Z,Han C,Xu Y,Yu X,Kang W,Xiang Y .2021 .The role of prostate-specific antigen and multiparametric magnetic resonance imaging in the diagnosis of granulomatous prostatitis induced by intravesical bacillus Calmette-Guérin vaccine therapy in patients with nonmuscle invasive bladder cancer. J Cancer Res Thera, 17 : 625-9.
Zaza MM,Salem TA,El-Sadat AM .2024 .Comparative study between mitomycin C versus Bacillus Calmette-Guérin (BCG) in high-risk non-muscle-invasive bladder cancer. Urologia J, 91 : 61-8.
Roumiguié M,Kamat AM,Bivalacqua TJ,Lerner SP,Kassouf W,Böhle A .2022 .International Bladder Cancer Group consensus statement on clinical trial design for patients with bacillus Calmette-Guérin-exposed high-risk non-muscle-invasive bladder cancer. Eur Urol, 82 : 34-46.
Culp MB,Soerjomataram I,Efstathiou JA,Bray F,Jemal A .2020 .Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol, 77 : 38-52.
Del Giudice F,Asero V,Bologna E,Scornajenghi CM,Carino D,Dolci V .2023 .Efficacy of different bacillus of Calmette-Guérin (BCG) strains on recurrence rates among intermediate/high-risk non-muscle invasive bladder cancers (NMIBCs): single-arm study systematic review, cumulative and network meta-analysis. Cancers, 15 : 1937-9.
Lv M,Shang S,Liu K,Wang Y,Xu P,Song H .2024 .Revitalizing Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer: Nanotechnology and Bioengineering Approaches. Pharmaceutics, 16 : 1067-9.
Yu SH,Wang CY,Wang SS,Li JR,Hung SC .2024 .Comparing Clinical Efficacy of Different Bacillus Calmette-Guérin Strains in Patients with T1 High Grade Bladder Cancer. Anticancer Res, 44 : 1299-307.
McElree IM,Steinberg RL,Mott SL,O'Donnell MA,Packiam VT .2023 .Comparison of sequential intravesical gemcitabine and docetaxel vs bacillus Calmette-Guérin for the treatment of patients with high-risk non-muscleinvasive bladder cancer. JAMA Network Open, 6(2) : e230849-54.
Al-Humairi RM .2023 .Systemic interleukin-6 response after intravesical instillation of Bacillus Calmette-Guérin and mitomycin C in superficial bladder cancer. Arch Razi Institute, 78 : 353-6.
Laukhtina E,Abufaraj M,Al-Ani A,Ali MR,Mori K,Moschini M .2022 .Intravesical therapy in patients with intermediate-risk non-muscle-invasive bladder cancer: a systematic review and network meta-analysis of disease recurrence. Eur Urol Focus, 8 : 447-56.
Guerrero-Ramos F,González-Padilla DA,González-Díaz A,de la Rosa-Kehrmann F,Rodríguez-Antolín A,Inman BA .2022 .Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial. World J Urol, 40 : 999-1004.
Babjuk M,Burger M,Capoun O,Cohen D,Compérat EM,Escrig JL .2022 .European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol, 81 : 75-94.
Coleman JA,Clark PE,Bixler BR,Buckley DI,Chang SS,Chou R .2023 .Diagnosis and management of nonmetastatic upper tract urothelial carcinoma: AUA/SUO guideline. J Urol, 209 : 1071-81.
0

Citations

0

Downloads

44

Views